Co-Diagnostics, Inc. Common Stock Asset Resilience Ratio
Co-Diagnostics, Inc. Common Stock asset resilience ratio. Co-Diagnostics, Inc. Common Stock (CODX) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CODX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Co-Diagnostics, Inc. Common Stock (2017–2025)
Asset resilience ratio of Co-Diagnostics, Inc. Common Stock from 2017 to 2025. This chart shows how Co-Diagnostics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read CODX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Co-Diagnostics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Co-Diagnostics, Inc. Common Stock (CODX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Co-Diagnostics, Inc. Common Stock maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Co-Diagnostics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Co-Diagnostics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Co-Diagnostics, Inc. Common Stock Asset Resilience Ratio by Year (2017–2025)
Co-Diagnostics, Inc. Common Stock asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Co-Diagnostics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $24.74 Million | -- |
| 2024-12-31 | 41.89% | $26.81 Million | $64.00 Million | -3.88pp |
| 2023-12-31 | 45.77% | $43.63 Million | $95.32 Million | -1.58pp |
| 2022-12-31 | 47.36% | $58.29 Million | $123.09 Million | +46.57pp |
| 2021-12-31 | 0.78% | $1.26 Million | $160.03 Million | -5.30pp |
| 2020-12-31 | 6.09% | $4.34 Million | $71.24 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $4.66 Million | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more